Literature DB >> 11642419

Persistent measles virus infection and otosclerosis.

H P Niedermeyer1, W Arnold, M Schuster, C Baumann, J Kramer, W J Neubert, R Sedlmeier.   

Abstract

The cause of otosclerosis is still unknown. Recently, measles virus involvement has been implicated. The aim of this study was to analyze the presence of measles virus RNA within the otosclerotic focus and to evaluate the perilymphatic antibody pattern. Bone and perilymph specimens from 40 patients with the spontaneous form of otosclerosis and from control patients were investigated by reverse transcription polymerase chain reaction (RT-PCR), Western blot techniques, and cell culture. By the use of RT-PCR, measles virus RNA could be detected in 32 patients, but not in controls. Analysis of perilymph revealed the presence of antibodies to N, F1, and M measles virus proteins in all cases, and antibodies against H protein in 2 additional cases. In preosteoblasts cultured from otosclerotic bone chips, no measles virus RNA could be amplified. We conclude that the spontaneous form of otosclerosis is, in the vast majority of cases, a measles virus-associated disease of the otic capsule.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642419     DOI: 10.1177/000348940111001001

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  3 in total

Review 1.  Etiopathogenesis of otosclerosis.

Authors:  Tamás Karosi; István Sziklai
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-09       Impact factor: 2.503

2.  The influence of measles vaccination on the incidence of otosclerosis in Germany.

Authors:  Wolfgang Arnold; Raymonde Busch; Andreas Arnold; Björn Ritscher; Albrecht Neiss; Hans Peter Niedermeyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-13       Impact factor: 2.503

3.  Restriction analysis of otosclerosis-associated CD46 splicing variants.

Authors:  Péter Csomor; Anita Szalmás; József Kónya; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-14       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.